×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RGNX – regenxbio inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RGNX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/11
03:47 pm
rgnx
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program [Yahoo! Finance]
Low
Report
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program [Yahoo! Finance]
1/11
03:00 pm
rgnx
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
Low
Report
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
12/19
10:04 am
rgnx
REGENXBIO (NASDAQ:RGNX) was given a new $45.00 price target on by analysts at Stifel Nicolaus.
Low
Report
REGENXBIO (NASDAQ:RGNX) was given a new $45.00 price target on by analysts at Stifel Nicolaus.
12/18
07:45 am
rgnx
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/18
07:05 am
rgnx
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/15
08:44 am
rgnx
REGENXBIO (NASDAQ:RGNX) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Medium
Report
REGENXBIO (NASDAQ:RGNX) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
11/27
07:01 pm
rgnx
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/26
05:35 pm
rgnx
Regenxbio files $300M mixed shelf offering [Seeking Alpha]
Low
Report
Regenxbio files $300M mixed shelf offering [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/8
04:45 pm
rgnx
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: PAKOLA STEVE
Medium
Report
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: PAKOLA STEVE
1/8
04:44 pm
rgnx
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Malzahn Craig
Medium
Report
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Malzahn Craig
1/8
04:43 pm
rgnx
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Simpson Curran
Medium
Report
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Simpson Curran
1/8
04:40 pm
rgnx
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Christmas Patrick J.
Medium
Report
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Christmas Patrick J.
1/8
04:33 pm
rgnx
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Chan Mitchell
Medium
Report
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Chan Mitchell
1/6
04:32 pm
rgnx
Form 4 REGENXBIO Inc. For: Jan 02 Filed by: Malzahn Craig
Medium
Report
Form 4 REGENXBIO Inc. For: Jan 02 Filed by: Malzahn Craig
1/6
04:32 pm
rgnx
Form 4 REGENXBIO Inc. For: Jan 02 Filed by: Simpson Curran
Medium
Report
Form 4 REGENXBIO Inc. For: Jan 02 Filed by: Simpson Curran
1/6
04:31 pm
rgnx
Form 4 REGENXBIO Inc. For: Jan 02 Filed by: PAKOLA STEVE
Medium
Report
Form 4 REGENXBIO Inc. For: Jan 02 Filed by: PAKOLA STEVE
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
12.1%
4/8 Form DEF 14A REGENXBIO Inc. For: May 29 8.8%
10/15 Form 8-K REGENXBIO Inc. For: Oct 11 8.8%
1/15 Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 7.1%
11/6 The FDA Paused This Biotech's Gene Therapy Study — And Shares Tumbled [Investor's Business Daily] 6.9%
8/28 REGENXBIO to Present at Upcoming Investor Conferences 5.4%
4/22 REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD 5.0%
12/12 We Think REGENXBIO (NASDAQ:RGNX) Can Afford To Drive Business Growth [Yahoo! Finance News] 4.8%
7/17 Regenxbio Inc (NASDAQ: RGNX) was given a new $84.00 price target on by analysts at Morgan Stanley. They now have a "buy" rating on the stock. 4.4%
1/9 REGENXBIO Reports Continued Progress Across Programs in Year-End 2019 Corporate Update 4.2%
4/8 Form DEF 14A REGENXBIO Inc. For: May 29 8.8%
10/15 Form 8-K REGENXBIO Inc. For: Oct 11 8.8%
1/15 Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 7.1%
11/6 The FDA Paused This Biotech's Gene Therapy Study — And Shares Tumbled [Investor's Business Daily] 6.9%
8/28 REGENXBIO to Present at Upcoming Investor Conferences 5.4%
4/22 REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD 5.0%
12/12 We Think REGENXBIO (NASDAQ:RGNX) Can Afford To Drive Business Growth [Yahoo! Finance News] 4.8%
7/17 Regenxbio Inc (NASDAQ: RGNX) was given a new $84.00 price target on by analysts at Morgan Stanley. They now have a "buy" rating on the stock. 4.4%
1/9 REGENXBIO Reports Continued Progress Across Programs in Year-End 2019 Corporate Update 4.2%
TOP News Decliners
3/11
Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating.
-17.1%
2/26 Form 8-K REGENXBIO Inc. For: Feb 26 -14.8%
10/30 Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue Injections [Seeking Alpha] -12.0%
10/11 Big Pharma Has Mad Love For These 2 Biotechs [The Motley Fool] -11.9%
3/6 Form SC 13G REGENXBIO Inc. Filed by: GIC Private Ltd -10.2%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder -10.0%
5/30 REGENXBIO Announces Completion of Dosing for Phase I/IIa Clinical Trial of RGX-314 in Wet AMD -9.9%
5/7 Q1/2019 3/31/2019 EPS -0.890 ZacksConsensus -0.850 ActVsEst (0.040) - Miss -8.5%
4/30 REGENXBIO To Host Conference Call on May 7 to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights -8.4%
8/8 Regenxbio Inc (NASDAQ: RGNX) was given a new $79.00 price target on by analysts at Evercore ISI. They now have a "buy" rating on the stock. -6.2%
2/26 Form 8-K REGENXBIO Inc. For: Feb 26 -14.8%
10/30 Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue Injections [Seeking Alpha] -12.0%
10/11 Big Pharma Has Mad Love For These 2 Biotechs [The Motley Fool] -11.9%
3/6 Form SC 13G REGENXBIO Inc. Filed by: GIC Private Ltd -10.2%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder -10.0%
5/30 REGENXBIO Announces Completion of Dosing for Phase I/IIa Clinical Trial of RGX-314 in Wet AMD -9.9%
5/7 Q1/2019 3/31/2019 EPS -0.890 ZacksConsensus -0.850 ActVsEst (0.040) - Miss -8.5%
4/30 REGENXBIO To Host Conference Call on May 7 to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights -8.4%
8/8 Regenxbio Inc (NASDAQ: RGNX) was given a new $79.00 price target on by analysts at Evercore ISI. They now have a "buy" rating on the stock. -6.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: